TY  - JOUR

T1  - Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

JO  - SKIN The Journal of Cutaneous Medicine

PY  - 2020/10/27

AU  - Cork M

AU  - Thaçi D

AU  - Eichenfield L

AU  - Arkwright P

AU  - Chen Z

AU  - Kamal M

AU  - O'Malley J

AU  - Bansal A

ED  - 

DO  - DOI: 10.25251/skin.4.supp.104

PB  - National Society for Cutaneous Medicine

VL  - 4

IS  - 6

SP  - s104

EP  - s104

Y2  - 2024/12/22

ER  -